Dosquet C, Coudert M C, Lepage E, Cabane J, Richard F
Centre de Transfusion, Laboratoire des Cytokines, Hôpital Saint-Louis, 75475 Paris Cedex 10, France.
Clin Cancer Res. 1997 Dec;3(12 Pt 1):2451-8.
Angiogenesis has an important role in the progression of solid tumors. Therefore, we measured the blood levels (ELISA) of angiogenic factors [basic fibroblast growth factor (bFGF), hepatocyte growth factor/scatter factor, and vascular endothelial growth factor (VEGF)] and soluble adhesion molecules [E-selectin, intercellular adhesion molecule (ICAM-1), platelet endothelial cell adhesion molecule-1, and vascular cell adhesion molecule-1] in 76 consecutive patients with untreated renal cell carcinoma and 41 healthy controls to evaluate their prognostic value. The serum levels of bFGF, hepatocyte growth factor, and VEGF were significantly higher in patients with renal cancer than they were in healthy subjects. bFGF and VEGF values were significantly higher in patients with disseminated cancer (N+ and/or M+) than they were in those with undisseminated (M-N-) cancer: median = 27 pg/ml, range = 5-118, n = 15 versus median = 8 pg/ml, range = 1-149, n = 61 (P = 10(-4)) for bFGF; and median = 883 pg/ml, range = 200-2317, n = 15 versus median = 278 pg/ml, range = 0-1704, n = 61 (P = 0.006) for VEGF. The blood levels of ICAM-1 and vascular cell adhesion molecule-1 were significantly higher, and the levels of E-selectin and platelet endothelial cell adhesion molecule-1 were significantly lower in patients with renal cancer than they were in controls. Plasma ICAM-1 was higher in metastatic patients (M+) than they were in nonmetastatic (M-) patients: median = 687 ng/ml, range = 294-1091, n = 12 versus median = 408 ng/ml, range = 217-1375, n = 64 (P = 10(-4)). ICAM-1 and bFGF blood values were correlated with the size of the primary tumor. The interleukin 6 and tumor necrosis factor-alpha (TNF-alpha) values of these patients have been previously published and are included in the survival analysis. Univariate analysis showed that bFGF, ICAM-1, interleukin 6, and TNF-alpha, before treatment, were prognostic factors. In multivariate analysis for proportional hazard regression, only TNF-alpha was an independent prognostic indicator, with a normal plasma TNF-alpha being highly predictive for a good prognosis in patients with untreated renal cell carcinoma.
血管生成在实体瘤进展中起重要作用。因此,我们检测了76例未经治疗的肾细胞癌连续患者和41例健康对照者血管生成因子[碱性成纤维细胞生长因子(bFGF)、肝细胞生长因子/分散因子和血管内皮生长因子(VEGF)]及可溶性黏附分子[E-选择素、细胞间黏附分子(ICAM-1)、血小板内皮细胞黏附分子-1和血管细胞黏附分子-1]的血中水平(酶联免疫吸附测定法),以评估其预后价值。肾癌患者血清中bFGF、肝细胞生长因子和VEGF水平显著高于健康受试者。播散性癌(N+和/或M+)患者的bFGF和VEGF值显著高于非播散性(M-N-)癌患者:bFGF的中位数=27 pg/ml,范围=5-118,n = 15,而中位数=8 pg/ml,范围=1-149,n = 61(P = 10^(-4));VEGF的中位数=883 pg/ml,范围=200-2317,n = 15,而中位数=278 pg/ml,范围=0-1704,n = 61(P = 0.006)。肾癌患者血中ICAM-1和血管细胞黏附分子-1水平显著升高,E-选择素和血小板内皮细胞黏附分子-1水平显著降低。转移性患者(M+)的血浆ICAM-1高于非转移性患者(M-):中位数=687 ng/ml,范围=294-1091,n = 12,而中位数=408 ng/ml,范围=217-1375,n = 64(P = 10^(-4))。ICAM-1和bFGF血值与原发肿瘤大小相关。这些患者的白细胞介素6和肿瘤坏死因子-α(TNF-α)值此前已发表,并纳入生存分析。单因素分析显示,治疗前bFGF、ICAM-1、白细胞介素-6和TNF-α是预后因素。在比例风险回归多因素分析中,只有TNF-α是独立的预后指标,血浆TNF-α正常对未经治疗的肾细胞癌患者预后良好具有高度预测性。